ClinicalTrials.gg
RecruitingNCT06383780Updated Jul 16, 2024

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

A Phase 3 interventional study of GP combined with Tislelizumab and TPC combined with Tislelizumab in Nasopharyngeal Carcinoma, sponsored by XIANG YANQUN. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by XIANG YANQUN · Phase 3, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 489 studies in Nasopharyngeal Carcinoma with a site in China — 203 open to participants now, 254 under way, 86 of them phase 3. Nasopharyngeal Carcinoma · China.

Planned enrollment
245th of 417
90 · median 126
Started
2024
with 46 others
Phase 3
121 of 489
61 open now
Primary completion
2027-05
later than 161 of 253 live
Registered
392nd of 489
by date

Among the 489 studies in Nasopharyngeal Carcinoma with a site in China, this one is the 245th largest by planned enrollment of the 417 interventional ones that give a count, is one of 47 that started in 2024, is one of 121 in phase 3, reaches primary completion later than 161 of the 253 other live ones, and was the 392nd registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

203 of the 489 studies in Nasopharyngeal Carcinoma with a site in China are open now. Recruiting first, the newest first:

198 more — sign in →

All 203 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 489 studies in Nasopharyngeal Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP(Gemcitabine combined with cisplatin) regimen in combination with Tislelizumab versus the TPC(cisplatin, nab-paclitaxel and capecitabine)regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

Read the detailed description

This study aims to evaluate the efficacy and safety of the GP regimen combined with Tislelizumab compared to the TPC regimen combined with Tislelizumab in the treatment of advanced first-line bone metastatic nasopharyngeal carcinoma patients in high-risk nasopharyngeal carcinoma areas through a prospective, open-label phase III clinical trial.

03

Conditions studied

  • Nasopharyngeal Carcinoma

Keywords

  • Nasopharyngeal Carcinoma With Bone Metastasis
  • immunochemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥ 18 years.
  2. Histology or cytology confirmed nasopharyngeal carcinoma.
  3. nasopharyngeal carcinoma of bone that is not suitable for local or radical therapy.
  4. Distant bone metastases confirmed by imaging (two images) or pathology (plus one image) (AJCC 8th, stage IVB), except for isolated local invasion of the base bone of the skull.
  5. With or without metastases from other organs, but lesions may be non-measurable distant organ metastases or lymph node lesions (as assessed by 1.1).
  6. Bone metastases may contain soft tissue components of osteolytic lesions.
  7. Patients have not previously received systemic therapy for advanced or metastatic disease, and prior induction chemotherapy, concurrent chemoradiotherapy, or chemotherapy must have been completed more than 6 months prior to enrollment. Previous radiotherapy or concurrent chemoradiotherapy should also be completed more than 6 months prior to enrollment.
  8. Expected survival ≥ 3 months.
  9. According to the (ECOG) criteria, the performance status score is 0 or 1.
  10. Good organ function: > 8.0 g/dl; (ANC) >1,500/mm3; count> 100,000/μl; Total ≤ 1.5 times the (ULN); and glutamate aminotransferase \< 2.5 ULN (upper limit of normal), (alanine aminotransferase and aspartate aminotransferase \< 5 ULN in patients with liver metastases), alkaline phosphatase\< 4 ULN; (PT) international normalized ratio/prothrombin time (PTT) \< 1.5 ULN, serum muscle;Anhydride\< 1.5ULN.
  11. Willing and able to comply with planned visits, treatment plans, laboratory tests, and other research procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with osteo-oligometastatic nasopharyngeal carcinoma.
  2. Previous history of severe to any component of other monoclonal antibodies or tislelizumab monoclonal mab.
  3. Patients have ≥ 1 organs or lymph node lesions that can be measured (assessed according to 1.1)
  4. No definitive surgical and/or radiotherapy for spinal cord compression, or for previously diagnosed and treated spinal cord compression, no evidence that the disease was clinically stable for ≥ 2 weeks prior to enrollment.
  5. Poorly controlled pleural effusion, pericardial effusion, or ascites requiring frequent drainage. Patients with indwelling catheters, such as PleurX ® catheters, are allowed to participate.
  6. Poorly controlled tumor-related pain. Patients requiring analgesic therapy must receive a stable dose before enrolling in the study. Patients who are candidates for palliative radiation therapy (e.g., bone metastases or metastases leading to nerve damage) should be treated prior to enrollment Lesions are treated. Prior to enrollment, if appropriate, consideration should be given to the need for further growth that may result in functional deficits or intractable pain (e.g., For example, asymptomatic metastases currently not associated with spinal cord compression) are treated locally-regionally.
  7. Poorly controlled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium> 12 mg/dL or corrected serum calcium higher than )
  8. with malignancies other than nasopharyngeal carcinoma within 5 years prior to enrollment, with negligible risk of metastasis or death (e.g., expected 5-year OS>90%) and expected radical results after treatment (e.g., adequately treated cervix).

    Localized cancer, basal or squamous cell skin cancer, localized prostate cancer treated for radical purposes, surgical treatment for radical purposes Ductal carcinoma in situ).

  9. History of diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis related to antiphospholipid syndrome, Wegener's granuloma disease, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with autoimmune-related hypothyroidism receiving stable dose thyroid hormone replacement therapy were eligible to participate in this study. Patients with type 1 diabetes who are controlled after receiving a stable insulin regimen are eligible to participate in this study.
  10. Receiving systemic immunostimulating drugs (including but not limited to interferon or IL-2) within 4 weeks prior to enrollment or within 5 half-lives of the drug (whichever is shorter).
  11. Receiving systemic (> 10 mg/d prednisone equivalent) or other systemic (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide and antibody) within 2 weeks prior to enrollment Tumor necrosis factor drugs [anti-TNF]). Topical, ocular, intra-articular, intranasal, and inhaled corticosteroids are permitted. Patients receiving acute low-dose systemic immunosuppressive agents (e.g., a single dose of dexamethasone for nausea) can be considered after a comprehensive discussion to decide whether to enroll in the study. Prophylactic steroids may be used in patients requiring baseline and follow-up MRI tumor evaluation who have had a previous allergic reaction to intravenous contrast.
  12. Patients who have previously undergone bone marrow transplantation or have previously undergone solid organ transplantation.
  13. History of idiopathic pulmonary fibrosis, drug-induced pneumonia, organic pneumonia (ie, bronchiolitis obliterans), history of idiopathic pneumonia or chest CT scan showing evidence of active pneumonia at screening.
  14. Active infection, including tuberculosis (clinical diagnosis includes clinical history, physical examination and imaging findings, and TB examination according to local medical practice), (known HBV surface antigen (HBsAg)), , or (HIV antibody positive). Patients with previous or cured HBV infection (defined as hepatitis B core antibody [anti-HBc] positive and HbsAg-negative) are eligible to participate in this study only if they are HBV DNA negative (HBV DNA ˂1000cps/ml). Patients with positive hepatitis C (HCV) antibodies have only polymerase chain reaction (PCR) that is HCV RNA negative is eligible to participate in this study.
  15. underlying medical conditions (e.g., dyspnea, pneumonia, pancreatitis, poorly controlled diabetes, active or poorly controlled infections, drugs, or alcohol) that the investigator believes may affect study drug administration and protocol adherence abuse, or mental illness).
  16. Presence of severe neurological or psychiatric disorders, including dementia and seizures.
  17. Accompanied by ≥ grade 2 peripheral neuropathy.
  18. Pregnant or lactating female patients.
  19. Major cardiovascular diseases, such as heart disease (grade II or higher, see Appendix 6), myocardial infarction within 3 months prior to enrollment, unstable arrhythmias or unstable angina. Known to have coronary artery disease, not satisfied Patients with standard congestive heart failure or \< 50% must be treated with an optimized stable medical regimen as determined by the treating physician, and if appropriate, a cardiologist.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    GP combined with Tislelizumab

    Gemcitabine combined with cisplatin regimen combined with Tislelizumab

    Drug: GP combined with Tislelizumab

  • Experimental
    TPC combined with Tislelizumab

    cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab

    Drug: TPC combined with Tislelizumab

Interventions

  • DrugGP combined with Tislelizumab

    Drug page: TislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Gemcitabine combined with cisplatin regimen combined with Tislelizumab

  • DrugTPC combined with Tislelizumab

    Drug page: TislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab

06

What researchers measure

Primary outcomes

  1. 1-year progression-free survival rate

    Time frame: up to 3 years

Secondary outcomes

  1. Overall survival

    Time frame: up to 3 years

  2. incidence of adverse events

    safety

    Time frame: up to 3 years

  3. rate of skeletal-related events

    Time frame: up to 3 years

  4. Biomarker response (EBV-DNA, bone metabolic markers)

    Time frame: up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The diagnosis, treatment regimen, toxicity and followup data will be shared once every year through email, phone or meeting.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
May 15, 2024
Primary completionEst.
May 15, 2027
CompletionEst.
May 15, 2029
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06383780
Lead sponsor
XIANG YANQUN
Responsible party
XIANG YANQUN (Professor, Sun Yat-sen University) — Sponsor-investigator
First posted
Apr 25, 2024
Start date
May 15, 2024
Primary completion
May 15, 2027 (estimated)
Completion
May 15, 2029 (estimated)
Last update
Jul 16, 2024

Study contacts

Yanqun Xiang
Contact
xiangyq@syscc.org.cn
18666096623
Guoying Liu
Contact
liugy0109@163.com
18127919832

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion